Organoids Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

The Organoids Market is projected to register a CAGR of 17.1% during the forecast period.
The COVID-19 pandemic had a significant impact on the organoids market. The increasing number of research and development activities for the introduction of the COVID-19 vaccine within a very limited time resulted in the higher adoption of organoids during the pandemic. The resemblance with actual organs, cell tropism, cell viability, and others are some of the key factors for the significant adoption of organoids during drug development at the time of the pandemic. For instance, an article published by the National Center for Biotechnology Information (NCBI) in February 2022, reported that organoids offered a significant pace in the research of COVID-19 by offering proper cellular heterogeneity, viral susceptibility, and appropriate host cell responses. Additionally, specific organoids were reported to be effective while identifying the treatment option for COVID-19. For instance, an article published by Springer Nature Limited in May 2021, reported that lung organoids had shown promising results while detecting the treatment options for the SARS-COV-2 virus during the pandemic.

Moreover, a research journal published by Springer Nature Limited in April 2022, reported that human pluripotent stem cell-derived airway organoids have shown certain specific characteristics of the SARS-COV-2 virus as well showed effectiveness while evaluating the options to limit the spread of the virus. This results in the increased use of organoids in the research field during the pandemic and fosters the market's growth. However, in the post-pandemic situation, the research studies and clinical trials increased significantly involving organoids. For instance, according to ClinicalTrials.gov, a total of 47 studies were reported involving organoids from 1st March 2021 till 3rd January 2023. Also, an article published by MDPI in June 2022, titled “3D Human Organoids: The Next “Viral” Model for the Molecular Basis of Infectious Diseases,” reported that organoids were proven to be efficacious in the research of a number of disorders, including COVID-19, HIV, Hepatitis B, Hepatitis C among others and gained its traction in the research of infectious disease in the post-pandemic situation. The above-mentioned factors are anticipated to contribute to the further growth of the market during the forecast period.

There are certain factors that are driving the market growth, including the rising prevalence of chronic diseases, the rising number of research on drug development involving organoids, and technological advancements in the development of organoids. The prevalence of chronic diseases, including cardiovascular disease, chronic kidney disease, and cancer, among others, is increasing globally. For instance, according to an article by the National Health Service (NHS) in May 2021, it was reported that an estimated 1.4 million people in the United Kingdom were suffering from atrial fibrillation in 2021. Additionally, according to a research article published by the Annals of Cancer Epidemiology in 2021, an estimated 235,760 new lung cancer cases were diagnosed in the United States in 2021. This rising number of patients suffering from a number of chronic diseases is increasing the healthcare burden and, alternatively, increasing the research and development initiatives for the introduction of novel drugs to be used in these chronic diseases. Additionally, owing to a better understanding of the disease condition and the effect of drugs on the actual organs, the adoption of organoid models is increasing for R&D purposes. According to ClinicalTrial.gov, a study titled “Intestinal Organoids (BIOÏDES)” started in September 2022 in France was aimed to develop a bio-collection of organoids from digestive biopsies with associated health data prior to testing them with potential therapeutic molecules for gastrointestinal disorders.

Furthermore, a number of rising initiatives in pharmaceutical research and development were observed by the major players for the development of organoids and the application of organoids to different indications, such as lung cancer, genetic abnormalities, chronic kidney disease, cardiovascular disorders, and colon cancer, among others. These initiatives are also fueling the demand for organoids in the research field. For instance, according to ClinicalTrials.gov, a total of 79 clinical studies are there for organoids till 31st December 2022. Apart from that, the latest technological advancements in the development of organoids models were further improving the outcomes of organoids in pharmaceutical research. For instance, in October 2022, AIM Biotech Pte. Ltd. introduced organiX System. This system is capable of adding vascularization and immune competence to organoids which can improve the shelf life of organoids during the research procedure.

Thus, the above-mentioned factors are attributed to the growing demand and adoption of organoids in the pharmaceutical research field and have been instrumental in the market's growth. However, certain clinical disadvantages, including functional disparities between the organoids and actual organs, are limiting the adoption rate of organoids during the study period.

Organoids Market Trends

Drug Discovery & Personalized Medicine Segment Expected to Contribute a Significant Proportion in the Market

Based on product type, the drug discovery & personalized medicine segment is anticipated to hold a significant market share during the study period. The increasing prevalence of chronic disease, along with rising initiatives by the major players to introduce blockbuster drugs in the market, is the primary reason attributed to the higher adoption of advanced technology, such as organoids, for drug discovery. For instance, in August 2022, Bayer AG introduced finerenone for the treatment of chronic kidney disease. Further, in a research study published by the National Center for Biotechnology Information (NCBI) in May 2022, it was reported that patient-derived pancreatic cancer organoids proved to be efficient in drug discovery for pancreatic cancer.

Along with that, the rising trend for personalized medicine is also fueling the adoption rate of organoids in the research industry. For instance, according to an estimation by Personalized Medicine Coalition, a total of 300 personalized medicine were there in the market in the United States till 2022. Also, according to another report by Personalized Medicine Coalition, it was reported that approximately 35% of the total drug approval by the Food and Drug Administration (FDA) is for personalized medicine in 2021. Additionally, according to a report by Alix Venture in 2021, owing to certain factors, including traceability and potential to capture patient and tumor type diversity, organoids are increasingly used to study personalized medicines, thus supporting the demand and adoption of organoids in the development of personalized medicine. Additionally, certain clinical benefits, including the potential for capturing patient and tumor type diversity and conservation of cellular composition, among others, are fostering the adoption rate of organoids in the research for personalized medicine. For instance, according to ClinicalTrial.gov, 31 clinical trials based on patient-derived organoids were reported till 31st December 2022.

Thus, owing to the above-mentioned factors, the drug discovery & personalized medicine segment is anticipated to capture a significant market share during the study period.

North America Contributed to the Largest Market Share During the Forecast Period

North America region is anticipated to hold a dominant position in the global organoids market during the study period. The large patient population suffering from chronic diseases, advanced healthcare facilities, the presence of key players in the region, and rising R&D expenditure by the Federal Government in the region are the driving factors for the growth of the market in this region. According to data from the Centers for Disease Control and Prevention (CDC), it was reported that a total of 20.1 million adults of age 20 years and older in the United States have Coronary Artery Disease in 2022. Also, according to American Liver Foundation, the estimated number of new cases of liver cancer was 42,230 in the United States in 2021. Furthermore, according to an estimation published by National Center for Biotechnology Information in May 2022, it was reported that there were around 233,900 new cancer cases reported in Canada in 2022. Moreover, several clinical trials have been reported for a number of chronic diseases involving organoids in this region. According to ClinicalTrial.gov, a study titled “Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer” was started on August 2018 in Texas, United States and is anticipated to complete in December 2024. This study aims to establish a biobank of patient-derived organoids for the treatment of lung cancer and examine the ex-vivo responses of the potential organoids to a number of chemotherapeutic agents. These above-mentioned factors collectively foster the demand and adoption of organoids in healthcare research in North America.

Moreover, rising healthcare R&D funding in North America is bolstering the introduction of advanced technology in the research field. According to a research report by the U.S. Government Accountability Office (GAO) in December 2022, the federal government of the United States increased funding for research and development for the Department of Health and Human Services from USD 60.0 billion in 2020 to USD 68.8 billion in 2021. Thus, the upgradation of research methodologies in the medical field fosters new and advanced equipment, such as organoids, for precise research results and results in the market's growth.

Additionally, ongoing regulations and the modernization act by the government of the United States is limiting the use of animal testing in the clinical trials of drugs. This results in adopting an alternative way of testing drugs during clinical trials and other drug development procedures. Thus the adoption rate of organoids in the research procedure is increasing. For instance, the FDA Modernization Act of 2022 would eliminate the necessity of animal testing for the development of any human drugs.

Thus, due to the above-mentioned factors, the organoids market is expected to witness consistent growth in North America over the forecast period.

Organoids Market Competitor Analysis

The Organoids Market is consolidated and consists of a few major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies among them are Cellesce Ltd, Merck KGaA, 3Dnamics Inc., R&D Systems, Inc., Hubrecht Organoid Technology, Definigen, Known Medicine, and Dynomics Inc.

Additional benefits of purchasing the report:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.